IBD先进疗法严重感染风险:法国全国队列研究
法国全国队列纳入2014-2024年启动治疗的219229例IBD患者,共309025次治疗。与氨基水杨酸相比,JAK抑制剂严重感染风险最高(aHR 1.63),乌司奴单抗最低(aHR 1.05),抗TNF和维得利珠单抗居中。
要点
- JAK抑制剂严重感染风险最高,乌司奴单抗最低。
- 抗TNF和维得利珠单抗风险居中,维得利珠单抗略高于抗TNF。
- 合并糖皮质激素使严重感染风险增加约2倍。
核心结论
- IBD患者中,JAK抑制剂严重感染风险最高,乌司奴单抗最低,抗TNF和维得利珠单抗居中。
研究设计与样本
- 法国全国队列研究,纳入2014-2024年启动治疗的219229例IBD患者,共309025次治疗,中位年龄41岁,52.0%为女性,45.3%为克罗恩病。
主要发现
- 中位随访1.0年,共发生15081例严重感染。
- 与氨基水杨酸相比,严重感染aHR:乌司奴单抗1.05(95%CI 0.98-1.11),抗TNF 1.29(95%CI 1.24-1.34),维得利珠单抗1.38(95%CI 1.30-1.46),JAK抑制剂1.63(95%CI 1.45-1.84)。
- 与抗TNF相比,严重感染aHR:乌司奴单抗0.81(95%CI 0.76-0.86),维得利珠单抗1.07(95%CI 1.01-1.13),JAK抑制剂1.27(95%CI 1.12-1.43)。
- 抗TNF和维得利珠单抗与皮肤、上呼吸道和中枢神经系统感染尤其相关;JAK抑制剂与疱疹病毒感染尤其相关;抗TNF与分枝杆菌感染尤其相关。
- 合并糖皮质激素和硫嘌呤/甲氨蝶呤分别使严重感染风险增加2.06倍(95%CI 1.98-2.14)和1.11倍(95%CI 1.06-1.16)。
临床怎么用
- 临床选择IBD先进疗法时,应评估严重感染风险,JAK抑制剂风险最高,乌司奴单抗最低。
- 使用JAK抑制剂需警惕疱疹病毒感染,使用抗TNF需警惕分枝杆菌感染。
- 应尽量减少合并糖皮质激素和硫嘌呤/甲氨蝶呤以降低感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Advanced therapy including biologics and Janus kinase inhibitors are commonly used to treat inflammatory bowel diseases. We aimed to assess the risk of serious infection in patients with inflammatory bowel diseases treated with advanced therapies. METHODS: This was a nationwide French cohort including patients with inflammatory bowel diseases aged >15 years, initiating treatment between 2014 and 2024: vedolizumab, ustekinumab, Janus kinase inhibitors, anti-tumor necrosis factors, or aminosalicylates. We assessed serious infection according to treatment exposure. Propensity score weighting accounted for indication bias. RESULTS: A total of 309,025 treatments were initiated in 219,229 patients: 27,514 initiated vedolizumab, 28,054 ustekinumab, 6439 Janus kinase inhibitors, 93,444 anti-tumor necrosis factors, and 153,574 aminosalicylates. The median age was 41 years (interquartile range, 29-55 years), 52.0% were women, and 45.3% had Crohn's disease. A total of 15,081 serious infections occurred over a median follow-up of 1.0 years. Compared with aminosalicylates, the adjusted hazard ratios for serious infections were 1.05 (95% confidence interval, 0.98-1.11) for ustekinumab, 1.29 (95% confidence interval, 1.24-1.34) for anti-tumor necrosis factors, 1.38 (95% confidence interval, 1.30-1.46) for vedolizumab, and 1.63 (95% confidence interval, 1.45-1.84) for Janus kinase inhibitors. Compared with anti-tumor necrosis factors, the adjusted hazard ratios were 0.81 (95% confidence interval, 0.76-0.86) for ustekinumab, 1.07 (95% confidence interval, 1.01-1.13) for vedolizumab, and 1.27 (95% confidence interval, 1.12-1.43) for Janus kinase inhibitors. Patterns were consistent across inflammatory bowel disease type. Anti-tumor necrosis factors and vedolizumab were particularly associated with skin, upper respiratory tract, and central nervous system infections. Janus kinase inhibitors were particularly associated with herpesvirus infections, and anti-tumor necrosis factor with mycobacterial infections. Concomitant corticosteroids and thiopurine/methotrexate increased the risks of serious infection by 2.06 (95% confidence interval, 1.98-2.14) and 1.11 (95% confidence interval, 1.06-1.16), respectively. CONCLUSIONS: Among patients with inflammatory bowel diseases, the risk of serious infection is highest with Janus kinase inhibitors, lowest with ustekinumab, and intermediate with anti-tumor necrosis factors and vedolizumab.
引用
- Bertrand A, Amiot A, Martin A, et al. Serious Infection in Inflammatory Bowel Diseases Patients Treated With Vedolizumab, Ustekinumab, Janus Kinase Inhibitors, Anti-Tumor Necrosis Factor or Aminosalicylates. Clin Gastroenterol Hepatol. 2026. PMID: 42055304. doi:10.1016/j.cgh.2026.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。